Overview
Nutritional supplements maker's fiscal Q3 sales rose 23% yr/yr, net loss widened
Company cites underutilized factory capacity as main reason for operating loss
Management expects net loss for Q4 and full fiscal year
Outlook
Company expects fourth-quarter sales revenue to increase versus prior year
Company anticipates net loss for fourth quarter and full fiscal year 2026
Company says new credit facility provides flexibility to support anticipated sales growth
Result Drivers
FACTORY UNDERUTILIZATION - Co said operating loss was mainly due to underutilization of factory capacities
PRIVATE-LABEL SALES - Growth in net sales was mainly driven by increased orders from a major customer and shipments to new customers
CARNOSYN SALES FLAT - CarnoSyn beta-alanine royalty, licensing and raw material sales revenue were relatively flat at $1.7 million during the third quarter
Company press release: ID:nGNX4cw4QQ
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
$35.48 mln
Q3 Net Income
-$4.31 mln
Q3 Gross Profit
$383,000
Q3 Operating Income
-$4.01 mln
Q3 Pretax Profit
-$4.24 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)